After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Groundbreaking treatment enhances the immune system’s ability to fight cancer Holy Cross Health now offers bispecific therapy, an innovative class of antibody drugs providing new hope for patients ...

In a perspective, Northwestern Engineering’s Chad Mirkin and Milan Mrksich argue that structural precision drives therapeutic ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...